Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device

This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.

Inclusion Criteria:

• Type 2 diabetes patients on stable metformin
• 18-70 years old
• Willing to perform at least 4 capillary blood glucose tests per day

Exclusion Criteria:

• Type 2 diabetes patients on any other antidiabetic treatment
• Patients listed in other trials
• Patients with significant diabetic organ disease or complications.

Other protocol-defined inclusion/exclusion criteria may apply